NCT03882840

Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I

Induced-T Cell Like NK Cellular Immunotherapy for Cancers That Are Lack of MHC-I Expression

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Second Affiliated Hospital of Guangzhou Medical University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

T effector cells and NK cells have mutual compensatory killing functions on various of cancer types. For those cancers that have no available targets for CAR-T cell generations, we established potent T cell-like NK cells (ITNK) with a specific conversion protocol for the T cells from the patient, to perform anti-cancer therapy, especially for those cancers that are lack of MHC-I molecule expression. We have finished pre-clinical investigations for the ITNK or CAR-ITNK cell therapy and scheduled to start a clinical phase I study.

Detailed description

One gene can be knockout of the T cells to produce a T-like NK cells which obtain killing function of both T effector cells and NK cells. We will collect appropriate patient's T cells, produce T-like NK cells (ITNK), and infuse the ITNK/CAR-ITNK cells back to the patients to treat various of cancers.

Conditions

• Anti-cancer Cell Immunotherapy
• T Cell and NK Cell

Interventions

Type	Name	Description
BIOLOGICAL	ITNK cell therapy	Infusion of ITNK/CAR-ITNK cells

Timeline

• Start date: 2019-01-01
• Primary completion: 2028-01-01
• Completion: 2035-01-01
• First posted: 2019-03-20
• Last updated: 2024-06-26

Locations

1 site across 1 country: China